HBV vaccine demonstrates encouraging results in early clinical trials

HBV vaccine demonstrates encouraging results in early clinical trials

A treatment regimen of low dose VBI-2601 (BRII-179) injections in patients with chronic hepatitis B exhibited positive safety, tolerability and efficacy, according to a poster presented at the International Liver Congress.“Without a functional cure for HBV infection, many of the 290 million people around the world infected with HBV will go on to develop significant and life-threatening complications from the disease such as liver decompensation and hepatocellular carcinoma,” Man-Fun Yuen, DSc, MD, PhD, professor at the University of Hong Kong and study presenter, said in a pressRead More

Share on facebook
Share on twitter
Share on linkedin